Next generation sequencing (NGS) has become a routine component in oncology diagnostics. As a result, NGS data volumes are growing exponentially. Through its clinical decision support software and services, QIAGEN is uniquely positioned to integrate and analyze this data in the context of other data to help guide drug development and clinical trials. Through illustration of industry-relevant use cases this webinar will explore the utility of QIAGEN’s large and diverse molecular database and its value for decision making across the drug development lifecycle.
Speaker: Sheryl Krevsky Elkin, PhD, Chief Scientific Officer, N-of-One, a QIAGEN company